T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
JPMorgan Chase
JPM
|
+$1.6B |
| 2 |
Verizon
VZ
|
+$1.3B |
| 3 |
US Bancorp
USB
|
+$1.26B |
| 4 |
Berkshire Hathaway Class B
BRK.B
|
+$1.26B |
| 5 |
Lam Research
LRCX
|
+$1.18B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amazon
AMZN
|
+$6.33B |
| 2 |
Tesla
TSLA
|
+$5.64B |
| 3 |
Alphabet (Google) Class C
GOOG
|
+$4.91B |
| 4 |
TMX
Terminix Global Holdings, Inc.
TMX
|
+$3.44B |
| 5 |
Meta Platforms (Facebook)
META
|
+$1.4B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 26.7% |
| 2 | Healthcare | 19.64% |
| 3 | Financials | 12.71% |
| 4 | Consumer Discretionary | 10.95% |
| 5 | Communication Services | 7.77% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
BCYC
1051
Bicycle Therapeutics
BCYC
$284M
| $10M | ﹤0.01% |
338,733
-78,607
| -19% | -$2.11M |
|
1052
Ovintiv
OVV
$17.5B
| $9.97M | ﹤0.01% |
196,717
-13,675
| -6% | -$715K |
|
|
EVA
1053
DELISTED
Enviva Inc.
EVA
| $9.84M | ﹤0.01% |
185,830
-121,457
| -40% | -$6.94M |
|
1054
Vir Biotechnology
VIR
$1.52B
| $9.76M | ﹤0.01% |
385,648
+39
| +0% | +$956 |
|
1055
Markel Group
MKL
$22.8B
| $9.75M | ﹤0.01% |
7,401
+812
| +12% | +$1M |
|
1056
Brookfield Asset Management
BAM
$87.1B
| $9.71M | ﹤0.01% |
+338,719
| New | +$10.2M |
|
1057
Petrobras
PBR
$115B
| $9.7M | ﹤0.01% |
910,677
-311,006
| -25% | -$3.76M |
|
1058
CI&T Inc
CINT
$465M
| $9.57M | ﹤0.01% |
1,471,732
+108,890
| +8% | +$854K |
|
1059
Organon & Co
OGN
$3.59B
| $9.5M | ﹤0.01% |
340,241
+3,036
| +0.9% | +$77.6K |
|
1060
Thryv Holdings
THRY
$96.9M
| $9.5M | ﹤0.01% |
500,164
+388
| +0.1% | +$7.57K |
|
1061
Pentair
PNR
$10.5B
| $9.33M | ﹤0.01% |
207,502
+348
| +0.2% | +$15.1K |
|
1062
DraftKings
DKNG
$12.7B
| $9.33M | ﹤0.01% |
819,310
+30,666
| +4% | +$427K |
|
1063
iShares Core S&P 500 ETF
IVV
$910B
| $9.27M | ﹤0.01% |
24,130
+18
| +0.1% | +$6.95K |
|
1064
Carlisle Companies
CSL
$15.2B
| $9.03M | ﹤0.01% |
38,297
+6,939
| +22% | +$1.79M |
|
1065
Badger Meter
BMI
$3.91B
| $9.01M | ﹤0.01% |
82,647
+6,285
| +8% | +$683K |
|
1066
Tenaya Therapeutics
TNYA
$164M
| $8.99M | ﹤0.01% |
4,472,202
+2,357,950
| +112% | +$5.76M |
|
1067
Belden
BDC
$5.39B
| $8.94M | ﹤0.01% |
124,408
-23,346
| -16% | -$1.69M |
|
1068
RH
RH
$3.41B
| $8.92M | ﹤0.01% |
33,391
+92
| +0.3% | +$24K |
|
|
UNVR
1069
DELISTED
Univar Solutions Inc.
UNVR
| $8.92M | ﹤0.01% |
280,407
+1,883
| +0.7% | +$54K |
|
|
1070
Berkshire Hathaway Class A
BRK.A
$1.09T
| $8.91M | ﹤0.01% |
19
| – | – |
|
1071
RXO
RXO
$3.85B
| $8.78M | ﹤0.01% |
+510,141
| New | +$9.05M |
|
|
SKX
1072
DELISTED
Skechers
SKX
| $8.77M | ﹤0.01% |
209,013
+5,609
| +3% | +$215K |
|
1073
iShares Core US Aggregate Bond ETF
AGG
$138B
| $8.67M | ﹤0.01% |
89,375
-1,629
| -2% | -$158K |
|
1074
National Bank Holdings
NBHC
$1.92B
| $8.66M | ﹤0.01% |
205,856
+16,957
| +9% | +$732K |
|
1075
MoonLake Immunotherapeutics
MLTX
$1.47B
| $8.64M | ﹤0.01% |
822,601
-46,787
| -5% | -$416K |
|
Similar funds
T. Rowe Price Associates's Q4 2022 Portfolio in Review
As of Q4 2022, T. Rowe Price Associates held 3,066 positions worth $622B, up 1.8% from $610B the previous quarter. Its ten largest holdings account for 27% of the portfolio.
T. Rowe Price Associates's Q4 2022 filing shows 113 new, 1,569 increased, 1,081 reduced and 107 closed positions. Its largest new stake was GE HealthCare: 6,360,001 shares worth $371M. The largest sale was Amazon, an estimated $6.33B.
By sector, the portfolio is most concentrated in Technology at 27% of assets, up from 26% a quarter earlier, followed by Healthcare and Financials.
- T. Rowe Price Associates's largest Q4 2022 buy was GE HealthCare: 6,360,001 shares worth $371M.
- T. Rowe Price Associates added most to JPMorgan Chase in Q4 2022, an estimated $1.6B increase.
- T. Rowe Price Associates's biggest Q4 2022 reduction was Amazon, cutting an estimated $6.33B.
- T. Rowe Price Associates fully exited Terminix Global Holdings, Inc. in Q4 2022, selling an estimated $3.44B.
- T. Rowe Price Associates's ten largest holdings make up 27% of its $622B portfolio in Q4 2022.
- T. Rowe Price Associates opened 113 new positions and closed 107 in Q4 2022.
- T. Rowe Price Associates's portfolio value rose 1.8% quarter-over-quarter to $622B.
Based on T. Rowe Price Associates's 13F filing for Q4 2022, filed 14 Feb 2023.